Compare Adaptive Biotechnologies Corp (ADPT) vs Opendoor Technologies Inc (OPEN) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

Opendoor Technologies (OPEN) trades at $4.79, down 2.24% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $1.30 billion on $4.37 billion revenue in 2025, with a negative net income margin of -35.25%. Recent news highlights a new CEO, a shift to the Opendoor 2.0 model, and the closure of India operations to focus on AI-driven efficiencies.

The outlook remains challenging with persistent losses and a highly leveraged balance sheet, though cost discipline and AI integration offer potential for margin improvement. Key risks include housing market volatility and high debt levels. Analyst consensus is cautious with 65.39% hold ratings, reflecting uncertainty around the path to profitability.